Independent induction of caspase-8 and cFLIP expression during colorectal carcinogenesis in sporadic and HNPCC adenomas and carcinomas

Cellular Oncology

Volumn 29, Issue 5, 2007, Pages 409-419

  Heijink, D M ^a   Kleibeuker, J H ^a   Jalving, M ^a   Boersma Van Ek, W ^a   Koornstra, J J ^a   Wesseling, J ^b   De Jong, S ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Apoptosis; Caspase 8; cFLIP; Colorectal cancer; HNPCC; TRAIL

Indexed keywords

CASPASE 8; FLICE INHIBITORY PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CELLULAR DISTRIBUTION; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG SENSITIVITY; ENZYME INDUCTION; EPITHELIUM; FAMILIAL CANCER; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UPREGULATION;

ADENOMA; AGED; AGED, 80 AND OVER; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 8; CELL PROLIFERATION; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; ENZYME INDUCTION; EPITHELIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SUBCELLULAR FRACTIONS;

EID: 34547863893     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. A. Alcivar, S. Hu, J. Tang and X. Yang, DEDD and DEDD2 associate with caspase-8/10 and signal cell death, Oncogene 22 (2003), 291-297.
2. A. Ashkenazi, Targeting death and decoy receptors of the tumour-necrosis factor superfamily, Nat. Rev. Cancer 2 (2002), 420-430.
3. A. Ashkenazi and V.M. Dixit, Death receptors: signaling and modulation, Science 281 (1998), 1305-1308.
4. A. Ashkenazi, R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrey, A. Hebert, L. DeForge, I.L. Koumenis, D. Lewis, L. Harris, J. Bussiere, H. Koeppen, Z. Shahrokh and R.H. Schwall, Safety and antitumor activity of recombinant soluble Apo2 ligand, J. Clin. Invest. 104 (1999), 155-162.
5. L. Besnault-Mascard, C. Leprince, M.T. Auffredou, B. Meunier, M.F. Bourgeade, J. Camonis, H.K. Lorenzo and A. Vazquez, Caspase-8 sumoylation is associated with nuclear localization, Oncogene 24 (2005), 3268-3273.
6. M.S. Bhojani, G. Chen, B.D. Ross, D.G. Beer and A. Rehemtulla, Nuclear localized phosphorylated FADD induces cell proliferation and is associated with aggressive lung cancer, Cell Cycle 4 (2005), 1478-1481.
7. K.M. Boatright and G.S. Salvesen, Mechanisms of caspase activation, Curr. Opin. Cell Biol. 15 (2003), 725-731.
8. D.W. Chang, Z. Xing, Y. Pan, A. Algeciras-Schimnich, B.C. Barnhart, S. Yaish-Ohad, M.E. Peter and X. Yang, c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis, EMBO J. 21 (2002), 3704-3714.
9. E. Cretney, A. Shanker, H. Yagita, M.J. Smyth and T.J. Sayers, TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer, Immunol. Cell Biol. 84 (2006), 87-98.
10. K.M. Debatin and P.H. Krammer, Death receptors in chemotherapy and cancer, Oncogene 23 (2004), 2950-2966.
11. E.G. de Vries, J.A. Gietema and S. de Jong, Tumor necrosis factor-related apoptosis-inducing ligand pathway and its therapeutic implications, Clin. Cancer Res. 12 (2006), 2390-2393.
12. X. Dolcet, D. Llobet, J. Pallares, M. Rue, J.X. Comella and X. Matias-Guiu, FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis, Lab. Invest. 85 (2005), 885-894.
13. T.M. Ganten, T.L. Haas, J. Sykora, H. Stahl, M.R. Sprick, S.C. Fas, A. Krueger, M.A. Weigand, A. Grosse-Wilde, W. Stremmel, P.H. Krammer and H. Walczak, Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs, Cell Death. Differ. 11(Suppl. 1) (2004), S86-S96.
14. J. Geller, I. Petak, K.S. Szucs, K. Nagy, D.M. Tillman and J.A. Houghon, Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin, Clin. Cancer Res. 9 (2005), 6504-6515.
15. N. Harper, S.N. Farrow, A. Kaptein, G.M. Cohen and M. Mac-Farlane, Modulation of tumor necrosis factor apoptosis-inducing ligand-induced NF-kappa B activation by inhibition of apical caspases, J. Biol. Chem. 276 (2001), 34743-34752.
16. A. Hernandez, Q.D. Wang, S.A. Schwartz and B.M. Evers, Sensitization of human colon cancer cells to TRAIL-mediated apoptosis, J. Gastrointest. Surg. 5 (2001), 56-65.
17. M. Jalving, S. de Jong, J.J. Koornstra, W. Boersma-van Ek, N. Zwart, J. Wesseling, E.G. de Vries and J.H. Kleibeuker, TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas, Clin. Cancer Res. 12 (2006), 4350-4356.
18. M. Jalving, J.J. Koornstra, S. de Jong, E.G. de Vries and J.H. Kleibeuker, Review article: the potential of combinational regimen with non-steroidal anti-inflammatory drugs in the chemoprevention of colorectal cancer, Aliment. Pharm. Therap. 21 (2005), 321-339.
19. J.R. Jass, L.H. Sobin and H. Watanabe, The World Health Organization's histologic classification of gastrointestinal tumors. A commentary on the second edition, Cancer 66 (1990), 2162-2167.
20. G. Jonsson, S. Paulie and A. Grandien, High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells, Anticancer Res. 23 (2003), 1213-1218.
21. T. Kataoka, The caspase-8 modulator c-FLIP, Crit. Rev. Immunol. 25 (2005), 31-58.
22. Y. Kim, N. Suh, M. Sporn and J.C. Reed, An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis, J. Biol. Chem. 277 (2002), 22320-22329.
23. J.J. Koornstra, M. Jalving, F.E. Rijcken, J. Westra, N. Zwart, H. Hollema, E.G. de Vries, R.W. Hofstra, J.T. Plukker, S. de Jong and J.H. Kleibeuker, Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction, Eur. J. Cancer 41 (2005), 1195-1202.
24. J.J. Koornstra, J.H. Kleibeuker, C.M. Van Geelen, F.E. Rijcken, H. Hollema, E.G. de Vries and S. de Jong, Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas, J. Pathol. 200 (2003), 327-335.
25. J.J. Koornstra, F.E. Rijcken, S. de Jong, H. Hollema, E.G. de Vries and J.H. Kleibeuker, Assessment of apoptosis by M30 immunoreactivity and the correlation with morphological criteria in normal colorectal mucosa, adenomas and carcinomas, Histopathology 44 (2004), 9-17.
26. C. Liedtke, N. Groger, M.P. Manns and C. Trautwein, Interferon-alpha enhances TRAIL-mediated apoptosis by upregulating caspase-8 transcription in human hepatoma cells, J. Hepatol. 44 (2006), 342-349.
27. D.B. Longley, T.R. Wilson, M. McEwan, W.L. Allen, U. Mc-Dermott, Galligan L. and P.G. Johnston, c-FLIP inhibits chemotherapy-induced colorectal cancer cell death, Oncogene 25 (2006), 838-848.
28. M. MacFarlane, N. Harper, R.T. Snowden, M.J. Dyer, G.A. Barnett, J.H. Pringle and G.M. Cohen, Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia, Oncogene 21 (2002), 6809-6818.
29. S. Mathas, A. Lietz, I. Anagnostopoulos, F. Hummel, B. Wiesner, M. Janz, F. Jundt, B. Hirsch, K. Johrens-Leder, H.P. Vornlocher, K. Bommert, H. Stein and B. Dorken, c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis, J. Exp. Med. 199 (2004), 1041-1052.
30. O. Micheau, A. Hammann, E. Solary and M.T. Dimanche-Boitrel, STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs, Biochem. Biochem. Res. Commun. 256 (1999), 603-607.
31. O. Micheau, M. Thome, P. Schneider, N. Holler, J. Tschopp, D.W. Nicholson, C. Briand and M.G. Grutter, The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex, J. Biol. Chem. 277 (2002), 45162-45171.
32. R. Midgley and D. Kerr, Colorectal cancer, Lancet 353 (1999), 391-399.
33. F. Palmerini, E. Devilard, A. Jarry, F. Birg and L. Xerri, Caspase 7 downregulation as an immunohistochemical marker of colonic carcinoma, Hum. Pathol. 32 (2001), 461-467.
34. Z.H. Qin, Y. Wang, K.K. Kikly, E. Sapp, K.B. Kegel, N. Aronin and M. DiFiglia, Pro-caspase-8 is predominantly localized in mitochondria and released into cytoplasm upon apoptotic stimulation, J. Biol. Chem. 276 (2001), 8079-8086.
35. W. Roth and J.C. Reed, FLIP protein and TRAIL-induced apoptosis, Vitam. Horm. 67 (2004), 189-206.
36. B.K. Ryu, M.G. Lee, S.G. Chi, Y.W. Kim and J.H. Park, Increased expression of cFLIP(L) in colonic adenocarcinoma, J. Pathol. 194 (2001), 15-19.
37. R.A. Screaton, S. Kiessling, O.J. Sansom, C.B. Millar, K. Maddison, A. Bird, A.R. Clarke and S.M. Frisch, Fas-associated death domain protein interacts with methyl-CpG binding domain protein 4: a potential link between genome surveillance and apoptosis, Proc. Natl. Acad. Sci. USA 100 (2003), 5211-5216.
38. Y. Shikama, L. Shen, M. Yonetani, J. Miyauchi, T. Miyashita and M. Yamada, Death effector domain-only polypeptides of caspase-8 and -10 specifically inhibit death receptor-induced cell death, Biochem. Biophys. Res. Commun. 291 (2002), 484-493.
39. M.B. Valnet-Rabier, B. Challier, S. Thiebault, R. Angonin, G. Margueritte, C. Mougin, B. Kantelip, E. Deconinck, J.Y. Cahn and T. Fest, c-Flip protein expression in Burkitt's lymphomas is associated with a poor clinical outcome, Br. J. Haematol. 128 (2005), 767-773.
40. C.M. van Geelen, E.G. de Vries, T.K. Le, R.P. van Weeghel and S. de Jong, Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines, Br. J. Cancer 89 (2003), 363-373.
41. C.M.M. van Geelen, J.L. Westra, E.G.E. de Vries, W. Boersman-van Ek, N. Zwart, H. Hollema, H.M. Boezen, N.H. Mulder, R.W.M. Hofstra, J.T.M. Plukker, S. de Jong, J.H. Kleibeuker and J.J. Koornstra, Prognostic significance of TRAIL, DR4 and DR5 expression in stage III colon cancer, J. Clin. Oncol. 31 (2006), 4998-5004.
42. B. Vogelstein, E.R. Fearon, S.R. Hamilton, S.E. Kern, A.C. Preisinger, M. Leppert, Y. Nakamura, R. White, A.M. Smits and J.L. Bos, Genetic alterations during colorectal-tumor development, N. Engl. J. Med. 319 (1988), 525-532.
43. H. Walczak, R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, C. Smith, P. Smolak, R.G. Goodwin, C.T. Rauch, J.C. Schuh and D.H. Lynch, Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo, Nat. Med. 5 (1999), 157-163.
44. W.S. Wang, P.M. Chen and Y. Su, Colorectal carcinoma: from tumorigenesis to treatment, Cell Mol. Life Sci. 63 (2006), 663-671.
45. X.D. Zhou, J.P. Yu, H.X. Chen, H.G. Yu and H.S. Luo, Expression of cellular FLICE-inhibitory protein and its association with p53 mutation in colon cancer, World J. Gastroenterol. 11 (2005), 2482-2485.